The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Leadership Team

 

Peder M. Andersen MD,
Chief Executive Officer
Tine Kold Olesen PhD,
Chief Operation Officer 
Niels Laursen MBA,
Chief Financial Officer
Professional experience Professional experience Professional experience
  • Peder Andersen holds 1,196,405 shares and 56,500 Investor warrants through his wholly owned company Fred Management ApS

  • Peder Andersen holds 1 139 905 shares through his wholly owned company Fred Management ApS

  • Chief Executive Officer at Biosergen AS since 2017

  • As CEO at Forward Pharma from 2012-2017, he was heading all development and IP activities and was instrumental in the IPO on the NY Nasdaq (USD 235m)

  • Managing director at Forward Pharma GmbH from 2009-2016

  • Vice President of clinical development at Astion Pharma from 2010-2012
  • Senior roles with experience from directing global, integrated development programs from early clinical stage to life cycle management primarily in the field of urology/oncology (Ferring 19 Years). The responsibilities included design and execution of novel strategies from early (first in man) stage through marketing authorization with key focus on CMC, clinical development, and regulatory interactions.

  • Junior roles within neurology (Novo nordisk, Glaxo Welcome and Orion)

  • Vice President in the development of biosimilars and active in alliance management (Alvotech 2 years)
  • Niels Laursen holds 20,000 shares and 20,000 Investor warrants

  • Currently Owner at Dwork, offering Strategic consulting and business development

  • Formerly CFO at Oncology Venture

  • CFO at Medical Prognosis Institute

  • Healthcare Innovation Manager at Blue Ocean Robotics

  • Director HR at TopoTarget A/S
Educational background Educational background Educational background
  • Doctor of Medicine (MD) from Copenhagen University
  • PhD. Medical and Health Sciences, Ghent University

  • MSc. Pharmaceutical Sciences, Copenhagen University

  • MBA. Imperial College, London
  • MBA, cand.merc from Copenhagen Business School